PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$102.00

16 Apr
2024

-4.350

OPEN

$105.27

-4.09%

HIGH

$106.52

280,336

LOW

$102.00

TARGET
$78.90 -22.6% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 73.7 xxx
DPS (cps) xxx N/A 37.2 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 137.7 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx N/A 50.5% xxx

Dividend yield today if purchased 3 years ago: 0.64%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.30

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 18c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx58.1
DPS All xxxxxxxxxxxxxxx30.0
Sales/Revenue xxxxxxxxxxxxxxx124.9 M
Book Value Per Share xxxxxxxxxxxxxxx132.9
Net Operating Cash Flow xxxxxxxxxxxxxxx64.8 M
Net Profit Margin xxxxxxxxxxxxxxx48.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx50.43 %
Return on Invested Capital xxxxxxxxxxxxxxx49.84 %
Return on Assets xxxxxxxxxxxxxxx33.77 %
Return on Equity xxxxxxxxxxxxxxx50.43 %
Return on Total Capital xxxxxxxxxxxxxxx68.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx38.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx121 M
Price To Book Value xxxxxxxxxxxxxxx49.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.4 M
Capex % of Sales xxxxxxxxxxxxxxx5.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx33 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.4

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

16/02/2024

5

Sell

$34.50

-66.18%

Pro Medicus grew 1H underlying pre tax profit strongly (up by 29%) according to Ord Minnett, but revenue outside the company's core US market was slightly weaker-than-expected and staffing costs increased.

The broker continues to believe the company is materially overvalued and the market is likely underestimating competitive threats. Sell. The $34.50 target is maintained after the impact from a weaker US dollar is offset by the time value of money.

Revenue in the 1H grew by 27% largely due to contract wins in the US. An interim dividend of 18cps was declared.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 38.00 cents and EPS of 75.40 cents.
Ord Minnett forecasts a full year FY25 dividend of 45.00 cents and EPS of 89.80 cents.

Bell Potter

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

PME STOCK CHART